KAPA

Kairos Pharma, Ltd.
Healthcare — PHARMACEUTICAL PREPARATIONS
Valhalla Score 44
A proprietary composite score from 0–100 measuring a stock's technical strength, sector-relative performance, and institutional flow activity. Higher scores indicate stronger setups.
$0.58

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

📊 Key Statistics

Market Cap$13M
P/E Ratio
EPS (TTM)
EPS YoY
Revenue YoY
Float
Short Float %
Inst. Ownership
Sector RS

📈 Fundamentals

ROE
ROIC
ROA
Current Ratio
Debt/Equity
Gross Margin
Net Margin
Dividend Yield
Next Earnings

Options Summary

Call OI
Put OI
P/C Ratio (OI)
Gamma Environment
Max Pain
Call Wall
Put Wall

🎯 Analyst Estimates

Consensus Target
High Target
Low Target
Analysts
Upside/Downside

📋 Quarterly Financials

Period Revenue Rev YoY EPS EPS YoY Gross Margin
Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

TypeStrikeExpSizePremiumTime
Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

TypePriceSizeValueVenueTime
Start Free Trial Full insider & congressional trade history

👤 Insider Trades

NameTypeSharesPriceDate
Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

InstitutionSharesValue% of Class

Start Your Free Trial

Have a referral code?

14-day free trial then $70/month. Cancel anytime.

Welcome to Valhalla